View in EDS

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer--results of a first-in-man dose-escalation study with a fixed-dose extension phase.

Saved in:
Bibliographic Details
Title: Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer--results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Authors: Isambert, N.1, Delord, J.-P.2, Soria, J.-C.3, Hollebecque, A.3, Gomez-Roca, C.2, Purcea, D.4, Rouits, E.4, Belli, R.4, Fumoleau, P.1 pfumoleau@cgfl.fr
Source: Annals of Oncology. May2015, Vol. 26 Issue 5, p1005-1011. 7p. 1 Diagram, 2 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdv031